Krueger JG et al. conducted a randomised, double-blind, placebo-controlled clinical trial in patients with psoriasis to evaluate the efficacy of secukinumab, a fully human monoclonal antibody that selectively inhibits IL-17A. Here, IL17A is linked to psoriasis.